JUNS 10-Q filed 2026-11-16 | Key takeaways
JUNS filed its 10-Q; the most relevant disclosure change is added Business combinations: Company entered a definitive Strategic Asset License Agreement with PharmAla Biotech Holdings Inc. on July 20, 2026 for exclusive U.S. rights to ALA-002, a proprietary MDMA formulation. Upfront consideration of $3,333,333 comprised of $1,500,000 cash and $1,83.
Read source-backed brief